相关实验视频

Updated: Jun 9, 2025

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

迪普萨科西德B通过促进自来抑制巨细胞脂质积累来减轻动脉样硬化

Wenjuan Quan^1,2, Taoli Sun¹, Bo Hu³

¹Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.

|October 26, 2024

概括

迪普萨科西德B (DB) 通过抑制泡细胞的形成来减少动脉样硬化. 这种天然化合物促进巨细胞自,这是清除细胞残渣的关键过程,为这种慢性炎症疾病提供了潜在的新疗法.

科学领域:

药理学药理学是指药理学的学科.
心血管研究研究心血管研究
细胞生物学细胞生物学

背景情况:

动脉样硬化是一种由脂质积累和泡细胞形成驱动的慢性炎症性疾病.
增强巨细胞自是一种有前途的动脉样硬化治疗策略.
来自Lonicerae flos的Dipsacoside B (DB) 显示出潜在的抗动脉样硬化性质.

研究的目的:

研究Dipsacoside B (DB) 对ApoE-/-小鼠动脉样硬化进展的影响.
探索DB在氧化LDL诱导泡细胞中的作用的潜在机制.
为了确定DB诱导的自是否介导其抗动脉样硬化作用.

主要方法:

在食高脂肪饮食的ApoE-/-小鼠中诱导了动脉样硬化,有或没有DB治疗.
在体外研究中使用了RAW264.7巨细胞,用氧化LDL (ox-LDL) 和DB治疗.
通过测量自细胞形成和自细胞标志物水平 (LC3-II,p62) 来评估自; 氨酸被用于抑制自.

主要成果:

在小鼠中,DB显著降低了动脉样硬化病变的大小,并改善了斑块稳定性,而不会影响肝/功能.
在剂量依赖的情况下,DB抑制了氧-LDL的吸收和巨细胞中的脂质积累.
在体内和体外,DB诱导了自,证实了蛋白质和mRNA水平上LC3-II和p62表达的增加.

结论:

迪普萨科西德B (DB) 具有显著的抗动脉样硬化作用.
DB通过诱导巨细胞自来抑制泡细胞的形成.
DB代表了一种潜在的动脉样硬化治疗剂,通过自调节起作用.

关键词:

单鱼类 (Lonicerae) 的牙线有沙宁华是什么意思?动脉样硬化动脉样硬化自自是自的过程.迪普萨科西德B B 泡细胞是一种泡细胞.

更多相关视频

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells

Published on: October 28, 2019

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

相关概念视频

Inflammation

Inflammation

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...